Comparative Pharmacology
Head-to-head clinical analysis: LORBRENA versus LYTGOBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORBRENA versus LYTGOBI.
LORBRENA vs LYTGOBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LORBRENA (lorlatinib) is a potent, selective, brain-penetrant inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinases. It inhibits ALK phosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK/ERK), and shows activity against most known ALK resistance mutations.
Futibatinib is a selective, irreversible inhibitor of fibroblast growth factor receptor (FGFR) 1-4. It binds covalently to the ATP-binding pocket of FGFR, inhibiting downstream signaling and reducing tumor cell proliferation and angiogenesis.
100 mg orally once daily with or without food.
4 mg orally once daily, taken on an empty stomach (at least 1 hour before or 2 hours after food), until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-30 hours), supporting once-daily dosing.
Terminal elimination half-life is approximately 9 hours (range 6–12 hours) following oral administration, supporting twice-daily dosing.
Primarily fecal (95%), with unchanged drug accounting for approximately 7% of the dose. Renal excretion is minimal (<1%).
Primarily fecal (approximately 81% of administered dose) with renal excretion accounting for <1% as unchanged drug. Biliary excretion contributes to fecal elimination.
Category C
Category C
Kinase inhibitor
Kinase inhibitor